Antiangiogenic therapy in brain tumor models

Journal of Neuro-Oncology

Volumn 45, Issue 3, 1999, Pages 247-255

  Bernsen, H J J A ^a   Van Der Kogel, A J ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Antiangiogenesis; Brain tumor vasculature; Glioma model

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; ENDOSTATIN; FR 111142; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GENISTEIN; GLUTATHIONE; IBUPROFEN; INTERLEUKIN 12; MEDROXYPROGESTERONE ACETATE; MINOCYCLINE; PACLITAXEL; PENICILLAMINE; PENTOSAN POLYSULFATE; PLASMINOGEN ACTIVATOR INHIBITOR; PROLACTIN; SURAMIN; TAMOXIFEN; TECOGALAN; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ANGIOGENESIS; BRAIN HEMATOMA; CANCER INHIBITION; CLINICAL TRIAL; DRUG EFFICACY; GENE THERAPY; GLIOBLASTOMA; HUMAN; IONIZING RADIATION; NONHUMAN; REVIEW; TUMOR MODEL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS;

EID: 0033503204     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006395802727     Document Type: Review

References (54)

1. Black P: Management of malignant glioma: role of surgery in relation to multimodality therapy. J Neurovirol 4: 227-236, 1998
2. DeAngelis LM: Brain tumor therapy: new horizons, new hope. Neurology 50: 1209-1210, 1998
3. Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H, Kristjansen PEG: Tumor angiogenesis - a new therapeutic target in gliomas. Acta Neurol-Scand 97: 52-62, 1998
4. Plate KH, Warnke PC: Vascular endothelial growth factor. J Neuro-Oncol 35: 365-372, 1997
5. Lamszus K, Schmidt NO, Jin L, Laterra J, ZagZag D, Way D, Witte M, Weinand M, Goldberg ID, Westphal M, Rosen EM: Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer 75: 19-28, 1998
6. Nakayama Y, Sueishi K, Oka K, Kono S, Tomonaga M: Stromal angiogenesis in human glioma; a role of platelet-derived endothelial cell growth factor. Surg Neurol 49: 181-187, 1998
7. Jensen RL: Growth factor-mediated angiogenesis in malignant progression of glial tumors: a review. Surg Neurol 49: 189-196, 1998
8. Folkman J: What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990
9. Gimbrone MA, Leapman S, Cotran RS, Folkman J: Tumour angiogenesis: iris neovascularisation at a distance from intraocular tumours. J Natl Cancer Inst 50: 219-228, 1973
10. - ical and biological considerations. Anticancer Res 17: 4121-4126, 1997
11. Wesseling P, Ruiter DJ, Burger PC: Angiogenesis in brain tumors. J Neuro-Oncol 32: 253-265, 1997
12. Vaupel P: Blood flow and metabolic environment of brain tumors. J Neuro-Oncol 22: 261-267, 1994
13. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995
14. Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmac Ther 63: 265-311, 1994
15. Fan TPD, Jaggar R, Bicknell R: Controlling the vasculature: angiogenesis, antiangiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 16: 57-66, 1995
16. Kuiper RAJ, Schellens JHM, Blijham GH, Beijnen Jh, Voest EE: Clinical research in antiangiogenic therapy. Pharmacol Res 37: 1-16, 1998
17. Kong HL, Crystal RG: Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 90: 273-286, 1998
18. Molema I, Griffioen AW: Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol Today 19: 392-394, 1999
19. Thorpe PE, Burrows FJ: Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 36: 237-251, 1995
20. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA: Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med 3: 437-442, 1997
21. Farrell CL, Megyesi J, Del Maestro RF: Effect of ibuprofen on tumor growth in the C6 spheroid implantation glioma model. J Neurosurg 68: 925-930, 1988
22. Bernsen HJJA, Rijken PFJW, Peters JPW, Bakker J, van der Kogel AJ: Delayed vascular changes after antiangiogenic therapy with anti-VEGF antibodies in human glioma xenografts in nude mice. Neurosurgery 43: 570-576, 1998
23. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS, Ferrara N: Inhibition of VEGF-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993
24. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/ vascular permeability factor antibody. Proc Natl Acad Sci 93: 14765-14770, 1996
25. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56: 1615-1620, 1996
26. Saleh M, Stacker SA, Wilks A: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56: 393-401, 1996
27. Saleh M: The role of tumour-delivered mIL-4 on rat C6 glioma regression: a paradox between tumour volume and tumour pathology. Int J Oncol 10: 1223-1227, 1997
28. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WKA: Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59: 895-900, 1999
29. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegl GP, Mao AJ, Bett AJ, Huckle WR, Thomas KA, Curiel DT: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95: 8795-8800, 1998
30. Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth P, McMahon G: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106, 1999
31. Stan AC, Nemati MN, Pietsch T, Walter GF, Dietz H: In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg 82: 1044-1052, 1995
32. Isobe N, Uozumi T, Kurisu K, Kawamoto K: Antitumor effect of TNP-470 on glial tumors transplanted in rats. Anticancer Res 16: 71-76, 1996
33. Isobe N, Uozumi T, Kurisu K, Kawamoto K: Experimental studies of the antitumor effect of TNP-470 on malignant brain tumors. Neuropediatrics 27: 136-142, 1996
34. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL: AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34: 869-875, 1994
35. Wilson JT, Penar PL: The effect of AGM-1470 in an improved intracranial 9L-gliosarcoma rat model. Neurol Res 16: 121-124, 1994
36. Taki T, Ohnishi T, Arita N, Hiraga S, Saitoh Y, Izumoto S, Mori K, Hayakawa T: Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis. J Neuro-Oncol 19: 251-258, 1994
37. Bernsen HJJA, Rijken PFJW, Peters JPW, Bakker JH, van der Kogel AJ: The effect of the antiangiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J Neuro-Oncol 38: 51-57, 1998
38. Gagliardi ART, Hadd H, Collins DC: Inhibition of angiogenesis by suramin. Cancer Res 52: 5073-5075, 1992
39. Coomber BL: Suramin inhibits C6 glioma-induced angiogenesis in vitro. J Cellular Biochem 58: 199-207, 1995
40. Takano S, Gately S, Engelhard H, Tsanaclis AMC, Brem S: Suramin inhibits glioma cell in vitro and in the brain. J Neuro-Oncol 21: 189-201, 1994
41. Bernsen HJJA, Rijken PFJW, Peters JPW, Bakker JH, Boerman RH, Wesseling P, van der Kogel AJ: Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neuro-Oncol 44: 129-136, 1999
42. Olson JJ, Polk DM, Reisner A: The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma. Neurosurgery 34: 297-308, 1994
43. Yoshida D, Ikeda Y, Nakazawa S: Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery 37: 287-293, 1995
44. Weingart JD, Sipos EP, Brem H: The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 82: 635-640, 1995
45. Kirsch M, Strasser J, Allende R, Bello L, Zhang JP, Black PM: Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 58: 4654-4659, 1998
46. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-292, 1998
47. Joe YA, Hong YK, Chung DS, Yang YJ, Kang JK, Lee YS, Chang SI, You WK, Lee H, Chung SI: Inhibition of malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int J Cancer 82: 694-699, 1999
48. Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao S, Chou P, Bouck NP: Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 56: 5684-5691, 1996
49. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR: Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 5: 293-300, 1998
50. Pilkington GJ, Bjerkvig R, de Ridder L, Kaaijk P: In vitro and in vivo models for the study of brain tumour invasion. Anticancer Res 17: 4107-4110, 1997
51. Bernsen HJJA, Rijken PFJW, Hagemeier NEM, van der Kogel AJ: A quantitative analysis of vascularization and perfusion of human glioma xenografts at different implantation sites. Microvasc Res 57: 244-257, 1999
52. Arosarena O, Guerin C, Brem H, Laterra J: Endothelial differentiation in intracerebral and subcutaneous experimental gliomas. Brain Res 640: 98-104, 1994
53. Devineni D, Kleinszanto A, Gallo JM: Uptake of temozolomide in a rat glioma model in the presence or absence of the angiogenesis inhibitor TNP-470. Cancer Res 56: 1983-1987, 1996
54. Ma J, Li FZ, Klein-Szanto A, Gallo JM: Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. Clin Exp Metast 16: 559-568, 1998